R&D channel feed

Rhythm’s drug shows 25% drop in BMI over one year for pa­tients with rare form of obe­si­ty

Last year

Up­dat­ed: ES­MO em­bar­go break leads can­cer con­fer­ence to re­lease da­ta for Bris­tol My­ers, J&J, No­var­tis, As­traZeneca

Last year
Pharma

Apel­lis’ C3 in­hibitor shows bio­mark­er im­pact in small PhII rare kid­ney dis­ease tri­al

Last year

Evelo dealt an­oth­er blow with a PhII fail, plans for strate­gic al­ter­na­tives

Last year

Ul­tragenyx to spin off com­pa­ny to de­vel­op ‘high risk, high re­turn’ gene ther­a­py for Alzheimer’s dis­ease

Last year
Startups

Ab­b­Vie’s Skyrizi helps more Crohn's pa­tients stay off steroids than J&J’s Ste­lara, PhI­II da­ta show

Last year
Pharma

Atom Bio­science rais­es $83M in Se­ries D for URAT1 in­hibitor in chron­ic gout treat­ment

Last year
Financing

Omeros drug fails a PhI­II kid­ney tri­al, stock near­ly halved

Last year

So­tio ter­mi­nates three tri­als study­ing its IL-15 su­per­ag­o­nist due to ‘in­suf­fi­cient ef­fi­ca­cy’

Last year

Biotech in Is­rael: Hold­ing on to busi­ness as usu­al amid un­cer­tain times

Last year
Startups

Sanofi’s eczema drug hits pri­ma­ry end­point in PhI­Ib tri­al, plans un­der­way for PhI­II in 2024

Last year

Am­gen gives first glimpse at PRMT5 in­hibitor, days af­ter Bris­tol My­ers put a $1B promise on the tar­get

Last year
Pharma

Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Last year
Pharma
FDA+

Cas­sa­va re­sponds to ac­cu­sa­tions of 'sci­en­tif­ic mis­con­duct,' re­it­er­ates sup­port of da­ta be­hind con­tro­ver­sial Alzheimer's drug

Last year

Most de­tailed hu­man brain map yet is ‘lay­ing the foun­da­tion for find­ing fu­ture cures’

Last year
In Focus

Ab­b­Vie and In­cyte re­port PhI­Ib vi­tili­go da­ta on oral JAKs an­a­lysts call ‘un­dif­fer­en­ti­at­ed’

Last year

Eli Lil­ly touts PhI­II mirik­izum­ab win in Crohn’s de­spite woes in oth­er con­di­tions

Last year

CRO at cen­ter of Pfiz­er’s Ly­me vac­cine study woes says FDA found no tri­al mis­con­duct 

Last year
Pharma
FDA+

eGe­n­e­sis brings kid­ney xeno­trans­plants clos­er to the clin­ic

Last year
Cell/Gene Tx

Mi­cro­bio­me start­up sells off as­sets; Faron's PhI/II da­ta in bone mar­row can­cer; AM Phar­ma touts bio­mark­er re­sults

Last year
News Briefing

Dan­ish biotech gears up for Phase IIb hidradeni­tis sup­pu­ra­ti­va tri­al fol­low­ing ear­ly clin­i­cal re­sults

Last year

Tem­pest eyes piv­otal tri­al for liv­er can­cer drug af­ter un­veil­ing ear­ly PFS, OS da­ta

Last year

No­vo stops late-stage kid­ney tri­al for semaglu­tide ear­ly for ef­fi­ca­cy, da­ta com­ing in 2024

Last year

Sana nar­rows fo­cus to ex vi­vo cell ther­a­pies, lays off 29% of staff to reach key clin­i­cal da­ta

Last year
People
Cell/Gene Tx
First page Previous page 65666768697071 Next page Last page
A service from the Financial Times